Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Perspectives from Caroline M. Apovian, MD; Susan P. Mollan, MBChB, FRCOphth, PhD In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Caviness Distinguished Professor of Medicine and Director of the UNC Diabetes Care Center. “Semaglutide has been a main stay of our efforts to reduce heart attack and stroke in people with diabetes.

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

Semaglutide use associated with increased risk for NAION at the 2-, 3-, and 4-year time point from the index date.